Table 2.

Multivariable regression model of predictors for changes in liver attenuation and liver enzymes

	Overall (n = 81)
Liver attenuation (HU)	∆	p
Single agent therapy	-5.54 (-10.64, -0.44)	0.034*
Obesity (BMI ≥ 30)	1.57 (-5.93, 2.79)	0.475
Baseline steatosis/steatohepatitis	1.38 (-5.93, 2.79)	0.692
Steroid use	-1.50 (-6.06, 3.06)	0.514
Baseline liver attenuation	-0.42 (-0.68, -0.16)	0.002*
Age	0.06 (-0.10, 0.22)	0.459
Gender	1.56 (-2.95, 6.07)	0.493
	Overall (n = 81)
Liver enzymes (AST)	∆	p
Single agent therapy	1.49 (-1.74, 4.72)	0.360
Obesity (BMI ≥ 30)	-0.23 (-3.01, 2.55)	0.871
Baseline steatosis/steatohepatitis	1.64 (-2.54. 5.82)	0.436
Steroid use	-3.21 (-6.08, -0.33)	0.030*
Baseline AST	-0.79 (-0.90, -0.68)	0.000*
Age	-0.03 (-0.13, 0.08)	0.633
Gender	0.64 (-2.23, 3.51)	0.659
	Overall (n = 81)
Liver enzymes (ALT)	∆	p
Single agent therapy	6.46 (-0.77, 13.69)	0.079
Obesity (BMI ≥ 30)	2.86 (-3.29, 9.00)	0.358
Baseline steatosis/steatohepatitis	6.85 (-2.50, 16.20)	0.148
Steroid use	-1.36 (-7.72, 5.01)	0.673
Baseline ALT	-0.79 (-0.90, -0.67)	0.000*
Age	-0.20 (-0.44, 0.03)	0.091
Gender	4.51 (-1.88, 10.91)	0.164

Note. Data are presented as mean change with the associated 95% confidence interval

HU Hounsfield unit